SCHEMBL4909692

SCHEMBL4909692

c1cc2cc(OCC3CCOCC3)cnc2[nH]1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PIK3CA P42336 6/20 0.44
MTOR P42345 3/20 0.44
PIK3CD O00329 3/20 0.44
CHRNA7 P36544 1/20 0.42
FGFR1 P11362 2/20 0.41
KDR P35968 2/20 0.41
FAAH O00519 1/20 0.40
HDAC1 Q13547 1/20 0.39
HDAC6 Q9UBN7 1/20 0.39
HDAC5 Q9UQL6 1/20 0.39
JAK2 O60674 2/20 0.38
PLK4 O00444 1/20 0.38
MAP4K4 O95819 1/20 0.38
ROS1 P08922 1/20 0.38
FLT1 P17948 1/20 0.38
MARK3 P27448 1/20 0.38
FLT4 P35916 1/20 0.38
FLT3 P36888 1/20 0.38
CLK2 P49760 1/20 0.38
CSNK1G2 P78368 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4901603 0.90 CHRNA7 (0.46) PIK3CAPIK3CDCHRNA7FGFR1KDR
SCHEMBL4855426 0.88 MAP2K1 (0.44) PIK3CAPIK3CDCHRNA7FGFR1KDR
SCHEMBL4784578 0.87 MTOR (0.43) PIK3CAMTORPIK3CDCHRNA7FGFR1
SCHEMBL14146936 0.85 SLC6A2 (0.55) SLC6A2SLC6A4HTR3AKCNH2EP300
SCHEMBL4782524 0.82 CHRNA7 (0.43) MTORPIK3CDCHRNA7FGFR1KDR
SCHEMBL4906119 0.81 PRKCZ (0.43) PIK3CAMTORPIK3CDFGFR1KDR
SCHEMBL4786058 0.81 SLC6A2 (0.56) CHRNA7ROCK1SLC6A2SLC6A4HTR3A
SCHEMBL4904462 0.76 PRKCZ (0.41) PIK3CAMTORPIK3CDFGFR1KDR
SCHEMBL4904458 0.76 PRKCZ (0.41) PIK3CAMTORPIK3CDFGFR1KDR
SCHEMBL1267865 0.74 CD274 (0.53) JAK1CD274

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8268858-B2 e.g. 5-(3-methoxybenzyloxy)-1H-pyrrolo[2,3-b]pyridine; protein kinases inhibitor; central nervous system disorders; Alzheimer's disease; Parkinson's disease; anticancer, antitumor agents; analgesics; cogestive heart failure; skin disorders; inflammatory bowel disorders; transplant rejection PLEXXIKON INC. (US) 2012-09-18 US disclosed
US-8268858-B2 e.g. 5-(3-methoxybenzyloxy)-1H-pyrrolo[2,3-b]pyridine; protein kinases inhibitor; central nervous system disorders; Alzheimer's disease; Parkinson's disease; anticancer, antitumor agents; analgesics; cogestive heart failure; skin disorders; inflammatory bowel disorders; transplant rejection PLEXXIKON INC. (US) 2012-09-18 US disclosed
US-8268858-B2 e.g. 5-(3-methoxybenzyloxy)-1H-pyrrolo[2,3-b]pyridine; protein kinases inhibitor; central nervous system disorders; Alzheimer's disease; Parkinson's disease; anticancer, antitumor agents; analgesics; cogestive heart failure; skin disorders; inflammatory bowel disorders; transplant rejection PLEXXIKON INC. (US) 2012-09-18 US disclosed
US-20080188514-A1 COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR PLEXXIKON INC 2008-08-07 US disclosed
US-20080188514-A1 COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR PLEXXIKON INC 2008-08-07 US disclosed
US-20080188514-A1 COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR PLEXXIKON INC 2008-08-07 US disclosed
WO-2008079909-A1 PYRROLO [2,3-B] PYRIDINES AS KINASE MODULATORS PLEXXIKON, INC. (US) 2008-07-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080188514-A1 COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR MAP3K20, MAP3K13, MAP3K8 PIK3CA 79/4885MTOR 52/4885PIK3CD 139/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.